Conference Coverage

VIDEO: Mobile stroke units aren’t just expensive toys


 

AT ANA 2017

– Mobile stroke units are specially equipped ambulance units designed to respond and deliver treatment to stroke patients as swiftly as possible. They are outfitted with a portable CT scanner, a mobile lab, and specialized personnel, including a telemedicine unit to assist with diagnosis. If a patient is experiencing an ischemic stroke, the unit can deliver thrombolytic therapy on the spot, circumventing travel to an emergency department.

But are they cost effective? There are 13 active units in the United States, and they’re not cheap. They cost about $3.5 million to build and operate over 5 years, according to James Grotta, MD, a neurologist with the Memorial Hermann Medical Group and director of stroke research at Memorial Hermann–Texas Medical Center, both in Houston.

In a video interview at the annual meeting of the American Neurological Association, Dr. Grotta described how his group is studying the impact of mobile stroke units on time to treatment and the long-term costs and cost savings associated with them in an ongoing clinical trial that is comparing outcomes in patients eligible for tissue plasminogen activator when treated by a mobile stroke unit versus standard prehospital triage and transport by emergency medical services. The study is comparing outcomes when the mobile stroke unit and emergency medical services are the primary responders on alternating weeks. Primary outcomes include cost-effectiveness, the change in Rankin scale score from baseline to 90 days, and the diagnostic agreement between a vascular neurologist in the mobile stroke unit and a telemedicine vascular neurologist consulted from the unit.

Mobile stroke units can even supplement existing health care in case of an emergency. Dr. Grotta also recounted how one unit assisted during the aftermath of Hurricane Harvey.

Recommended Reading

Stopping statins after stroke may up recurrent stroke risk
MDedge Hematology and Oncology
New findings from first all-female TAVR registry
MDedge Hematology and Oncology
Undiagnosed AF common in higher-risk patients
MDedge Hematology and Oncology
VIDEO: Rivaroxaban plus aspirin cut cardiovascular events in stable patients
MDedge Hematology and Oncology
VIDEO: Educational intervention boosts A fib anticoagulation
MDedge Hematology and Oncology
Dabigatran, rivaroxaban linked to slight increase in GI bleeding risk
MDedge Hematology and Oncology
Oral anticoagulation ‘reasonable’ in advanced kidney disease with A-fib
MDedge Hematology and Oncology
LDL levels below 10 mg/dL shown safe, effective
MDedge Hematology and Oncology
Surgical left atrial appendage closure slashes stroke risk
MDedge Hematology and Oncology
MI, stroke risk from HFrEF surpasses HFpEF
MDedge Hematology and Oncology

Related Articles